Dose and duration of fenfluramine-phentermine therapy impacts the risk of significant valvular heart disease

Authors: Lepor N.E.; Gross S.B.; Daley W.L.; Samuels B.A.; Rizzo M.J.; Luko S.P.; Hickey A.; Buchbinder N.A.; Naqvi T.Z.

Source: The American Journal of Cardiology, Volume 86, Number 1, 1 July 2000 , pp. 107-110(4)

Publisher: Elsevier

Language: English

Document Type: Short communication

DOI: http://dx.doi.org/10.1016/S0002-9149(00)00840-7

Affiliations: 1: aHeart Center of Los Angeles, , Los Angeles, California, USA

Publication date: 2000-07-01

• In this: publication
• By this: publisher
• In this Subject: Cardiovascular Medicine
• By this author: Lepor N.E. ;  Gross S.B. ;  Daley W.L. ;  Samuels B.A. ;  Rizzo M.J. ;  Luko S.P. ;  Hickey A. ;  Buchbinder N.A. ;  Naqvi T.Z.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers